Clinical Trial Search

Primary: Median Score on the Feasibility of Intervention Measure (FIM) Survey — 5 score on a scale

Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares

Primary: Incidence of Serious Adverse Device Effects in the Treatment Group Compared to the Control Group. — 0; 0 Participants

Primary: Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS) — 16.59; 19.35…

Primary: Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 999.27; 7981.53 hour*nanomole/Liter

Primary: Progression-free Survival (PFS) as Determined by the Investigator — 9.89; 8.31 months — p=0.9912

Primary: Change From Baseline in Five Times Sit-to-stand Time — -0.76; -1.33 seconds — p=0.436

Primary: Change in Temporary Threshold Shift at 4 kHz--Intent To Treat (ITT) Population — 3.23; 1.32; 3.81; 4.07 dbHL — p=<0.05

Primary: Number of Patients Experiencing P. Vivax Recurrence — 48; 11; 2 Participants

Primary: Mass Balance Recovery of Total Radioactivity in Urine and Faeces: Amount Excreted Within the Time Interval From 0 to the Time of the Last Quantifiable Data Point as a…

Primary: 1_Change From Baseline in Pre-dose Morning Forced Expiratory Volume in the 1st Second (FEV1) -- at Week 26 — 0.082; 0.001 litre — p=< 0.001

Primary: Participants With a Complete Response for Cytokine Release Syndrome (CRS) — 15 Participants

Primary: Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4 — -1.755; -9.253 mmHg

Primary: Change in Percentage of CGM Glucose Readings > 120 mg/dL — 25.0; 21.5; 16.9; 21.7 percentage of CGM readings

Primary: Number of Participants Achieving Clinical Cure — 5 Participants